Singapore: Clinical stage biotech Lion TCR bags $20m from Yashang Capital, others

Singapore-based clinical stage biotech firm Lion TCR has raised $20 million in a Series A funding round from new investors Yashang Capital and US-based early stage investor Westlake Ventures Capital apart from undisclosed existing investors.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at